Cerveau Technologies Inc. Announces Expanded Research Access to Novel Tau Imaging Agent
BOSTON--(BUSINESS WIRE)--Aug 7, 2018--Cerveau Technologies, Inc. today announced expansion of the production network for its novel tau imaging agent, [ 18 F]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s Disease. This expansion has been driven by the increasing interest in [ 18 F]MK-6240 as a developmental and investigational tool in clinical trials.
In recent weeks, Cerveau has qualified production sites in Hayward, CA; Houston, TX; Phoenix, AZ; Birmingham, AL; as well as academic sites at John Hopkins University and Columbia University. These six (6) sites join an already existing network of ten (10) production sites in the US, Canada, Australia, and Belgium.
Twenty additional sites in Canada (1), the United States (3) Japan (4), Australia (4), Europe (4), and China (4) are undergoing capital expansion, technology transfer and start up processes. These sites will support a range of research and therapy clinical trial initiatives globally. This extensive production network will ultimately support imaging biomarkers licensed by Cerveau and its partners in research and development.
“Cerveau is focused on increasing access to the transformative technologies that we believe have the potential to advance brain health,” says Rick Hiatt, President and Chief Executive Officer, Cerveau Technologies, Inc. “This expansion of the biomarker production network underscores our commitment to the broader scientific research community and our support of industry’s initiatives to combat neurodegenerative disorders.”
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180807005304/en/
CONTACT: Cerveau Technologies, Inc.
Rick Hiatt, 617-906-2715
KEYWORD: UNITED STATES NORTH AMERICA CANADA MASSACHUSETTS
INDUSTRY KEYWORD: TECHNOLOGY OTHER TECHNOLOGY HEALTH BIOTECHNOLOGY MEDICAL DEVICES PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: Cerveau Technologies, Inc.
Copyright Business Wire 2018.
PUB: 08/07/2018 07:00 AM/DISC: 08/07/2018 07:00 AM